New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023
Gain insight into expert faculty perspectives as they discuss recent key studies from EHA 2023 on BTK inhibition in chronic lymphocytic leukemia and the potential implications for clinical practice.